-
Mashup Score: 0U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab | Eli Lilly and Company - 2 year(s) ago
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines | Eli Lilly and Company - 2 year(s) ago
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Healthcare Professionals, Latest HeadlinesTweet-
Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines including Phase 3 trial of #obesity medication with 3 gut hormones #glp1 #glucagon and #gip | @LillyPad Eli Lilly and Company https://t.co/0YCsRFi4Wv
-
-
Mashup Score: 0Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines | Eli Lilly and Company - 2 year(s) ago
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Cardiologists, Latest HeadlinesTweet-
Lilly Announces new treatments for #T2D and #Obesity but they maybe forget that cardiologists manage many obese patients š¤ https://t.co/8BLRV8AvC2
-
-
Mashup Score: 1Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines | Eli Lilly and Company - 2 year(s) ago
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Cardiologists, Latest HeadlinesTweet-
Exciting! @LillyPad Triagonist, retratrutide, moving to ph3 with exciting results to date. https://t.co/ntC52Y3q1P https://t.co/LMaX0sfhtM
-
-
Mashup Score: 49
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Cardiologists, Latest HeadlinesTweet-
RT @DanielJDrucker: Some news #Tirzepatide #Obesity @US_FDA @LillyPad https://t.co/GbyXZe1aQ7 https://t.co/FNMl8Z323T
-
-
Mashup Score: 7
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Healthcare Professionals, Latest HeadlinesTweet-
Lilly receives U.S. FDA Fast Track designation for #tirzepatide for the treatment of adults with #obesity , or overweight with weight-related comorbidities | Eli Lilly and Company https://t.co/VWEP2ZXPTY
-
-
Mashup Score: 9
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Cardiologists, Latest HeadlinesTweet-
RT @DanielJDrucker: Some news #Tirzepatide #Obesity @US_FDA @LillyPad https://t.co/GbyXZe1aQ7 https://t.co/FNMl8Z323T
-
-
Mashup Score: 3
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Healthcare Professionals, Latest HeadlinesTweet-
Lilly has announced that Taltz (ixekizumab) is now available as a Citrate-Free Formulation to reduce injection site pain for patients with psoriasis, psoriatic arthritis, spondyloarthritis & nonradiographic axial spondyloarthritis. https://t.co/mTBl9siLED https://t.co/TCFqdK58dA
-
-
Mashup Score: 10
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Healthcare Professionals, Latest HeadlinesTweet-
Lilly has announced that Taltz (ixekizumab) is now available as a Citrate-Free Formulation to reduce injection site pain for patients with psoriasis, psoriatic arthritis, spondyloarthritis & nonradiographic axial spondyloarthritis. https://t.co/kFQVUdalQp https://t.co/UKtFzReIe6
-
-
Mashup Score: 0
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Healthcare Professionals, Latest HeadlinesTweet-
$LLY: https://t.co/H8JOxDgd2V $SNY: https://t.co/UVmorPAtBu
-
U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab | Eli Lilly and Company https://t.co/yUfU6ahIhK